TP53 mutations, detected in approximately 40–69% of real-world cases, are a well-recognized negative prognostic factor in EGFR-mutant advanced NSCLC, often associated with high burden of disease and presence of liver metastasis [18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.